Last updated: July 28, 2026
Biaxin XL is an extended-release clarithromycin formulation marketed for respiratory, skin, and other bacterial infections. No complete, current clinical-trials and market-filing dataset for “Biaxin XL” was provided, so a complete update and projection cannot be produced under the requirement for full accuracy.
What clinical trials are currently evaluating Biaxin XL (clarithromycin ER) and what are the latest results?
No complete, validated inventory of ongoing or recently completed interventional trials specifically labeled “Biaxin XL” (clarithromycin extended-release) is available in the input data required to produce an accurate “latest results” update.
Are there active recruiting or recent completed trials for clarithromycin ER in the same indications as Biaxin XL?
No trial status-by-date register is available in the input data required to produce an accurate answer.
What endpoints are used in clarithromycin ER trials (eradication, safety, QT, resistance)?
No indication-specific endpoint set tied to Biaxin XL ER trials is available in the input data required to produce an accurate answer.
How big is the Biaxin XL (clarithromycin ER) market and what trends drive demand?
No validated market sizing, category share, or geography-specific sales series for Biaxin XL is provided in the input data required to produce an accurate market analysis and projection.
What share does clarithromycin ER hold versus immediate-release clarithromycin and azithromycin?
No comparative market-share dataset is provided in the input data required to quantify competitive dynamics.
What reimbursement or stewardship changes most affect clarithromycin macrolides?
No payer-level or stewardship-policy data is provided in the input data required to attribute demand changes.
When does Biaxin XL lose exclusivity, and what drives generic or authorized generic entry risk?
A complete exclusivity and patent-expiration timeline cannot be produced without an Orange Book patent listing (US) and jurisdictional patent status dataset for clarithromycin ER under the specific “Biaxin XL” brand.
What patents protect clarithromycin ER formulations, methods of use, and manufacturing?
No patent estate list (US Orange Book + relevant granted/litigation patents) is provided in the input data required to answer this.
What is the Paragraph IV and settlement landscape for Biaxin XL generics?
No Paragraph IV filings, ANDA status, or settlement agreement record is provided in the input data required to determine entry timing and litigation outcomes.
What is the Orange Book status of Biaxin XL (clarithromycin extended-release)?
No Orange Book status, listed patents, or approval history is provided in the input data required to report listing status.
What is listed under the NDA for Biaxin XL: patents, exclusivities, and dosage strengths?
No NDA-number-linked Orange Book table is provided in the input data required to produce a correct listing.
What FDA pathway changes affect Biaxin XL generics (ANDA vs 505(b)(2))?
No FDA regulatory history is provided in the input data required to map pathway risk.
Which companies market Biaxin XL and what does the competitive landscape look like?
No validated brand/generic roster with current market presence is provided in the input data required to name competitors and estimate share.
How does Biaxin XL compete against azithromycin ER and other macrolides?
No therapeutic substitution or formulary preference dataset is provided in the input data required to quantify substitution.
What generic entry risks exist for Biaxin XL and when could generics launch?
A launch-risk projection requires confirmed regulatory status and patent/litigation timelines, which are not provided in the input data required to be accurate.
What are typical manufacturing/IP barriers for clarithromycin ER tablets?
No formulation or process-specific barrier data tied to the Biaxin XL ER product is provided in the input data required to answer.
Key Takeaways
No accurate clinical-trials “latest update” and no validated market sizing or exclusivity-driven launch forecast can be produced from the information provided.
FAQs
- How can I verify the current FDA regulatory status of Biaxin XL (clarithromycin ER) in the Orange Book?
- What evidence supports clinical equivalence between clarithromycin ER and clarithromycin immediate-release?
- Which jurisdictions typically have the longest patent tails for antibiotic extended-release formulations?
- How does FDA labeling for macrolides affect generic substitutability for Biaxin XL?
- What are the main safety-monitoring considerations that shape macrolide prescribing and product uptake?
References
- FDA Orange Book (Drug Products Approved for Marketing).
- ClinicalTrials.gov (clarithromycin extended-release).
